Let’s Connect
Sharing Knowledge Through
Communication
Since 2007

Oligonucleotide Safety Working Group

chart

Latest Research Papers & Updates

Nonclinical Safety

Assessment of Oligonucleotide Therapeutics. A collaborative white paper summarizing current best practices in genotoxicity, safety pharmacology, and immunomodulation.

Addressing Off-Target Effects

Oligonucleotide Development. Insights from OSWG subcommittee on strategies for predicting and mitigating unintended biological interactions.

Reproductive Toxicology

Key findings on developmental and reproductive safety from industry and regulatory discussions.

Addressing Off-Target Effects

Oligonucleotide Development. Insights from OSWG subcommittee on strategies for predicting and mitigating unintended biological interactions.

Building Research,
Pioneering Communities

Through
Research
Knowledge
Sharing

Working together to
build knowledge

shape standards, and advance safe therapies worldwide.

Working together to
build knowledge
shape standards, and advance safe therapies worldwide.
Advance Safe
Development
We aim to establish best practices for nonclinical safety evaluation of oligonucleotide therapeutics. By aligning across industry, regulators, and researchers, we ensure safe and effective therapies reach patients faster.
Featured Publications

Explore our most recent and impactful research, showcasing key findings that shape the future of oligonucleotide safety evaluation.

Nonclinical Safety Evaluation of Oligonucleotides

Frameworks for assessing early-stage safety while protecting patients.
Learn More

Off-Target Effects in Oligonucleotide Research

Methods to detect and reduce unintended therapeutic effects.
Learn More

Carcinogenicity Assessment
Strategies

Current models for evaluating cancer risks in development.
Learn More